Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial

Objectives: Risk factors for cardiovascular events are well established in general populations and those with diabetes but have been sparsely studied in impaired glucose tolerance (IGT). We sought to identify predictors of (1) a composite cardiovascular outcome (cardiovascular death, non-fatal myoca...

Full description

Bibliographic Details
Main Authors:	Preiss, D, Thomas, L, Sun, J, Haffner, S, Holman, R, Standl, E, Leiter, L, Mazzone, T, Rutten, G, Tognoni, G, Martinez, F, Chiang, F, Califf, R, McMurray, J
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2012

Similar Items

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Preiss, D, et al.
Published: (2013)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
by: Califf, R, et al.
Published: (2008)

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
by: Mcmurray, J, et al.
Published: (2011)

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Latini, R, et al.
Published: (2013)

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
by: Currie, G, et al.
Published: (2017)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
by: Krum, H, et al.
Published: (2010)

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
by: Sharma, A, et al.
Published: (2016)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk
by: Bethel, M, et al.
Published: (2013)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
by: Bethel, M, et al.
Published: (2013)

Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study
by: Shen, L, et al.
Published: (2012)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
by: Shen, L, et al.
Published: (2013)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
by: Califf, R, et al.
Published: (2003)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
by: Yates, T, et al.
Published: (2014)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
by: Yates, T, et al.
Published: (2014)

Comparison of in vivo tests for glucose tolerance in subjects with normal, impaired glucose tolerance and type 2 diabetes
by: Hermans, M, et al.
Published: (1996)

Modeling the oral glucose tolerance test in normal and impaired glucose tolerant states: a population approach
by: Theodorakis, M, et al.
Published: (2016)

Early detection of impaired glucose tolerance in young adults
by: May, Khin Soe, et al.
Published: (2013)

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
by: Gerstein, H, et al.
Published: (2006)

Diet and other health-related behaviors of individuals with impaired glucose tolerance, cardiovascular disease (CVD) or CVD risk: A global view from the NAVIGATOR study
by: Bales, C, et al.
Published: (2013)

The role of nicotinamide nucleotide transhydrogenase in insulin secretion and impaired glucose tolerance
by: Freeman, H, et al.
Published: (2005)

Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial
by: Wamil, M, et al.
Published: (2020)

Expert Workshop on Impaired Glucose Tolerance Held in London, UK - 29 March 1995 - Introduction
by: Holman, R
Published: (1996)

'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance.
by: Page, R, et al.
Published: (1993)

Role of the transcription factor sox4 in insulin secretion and impaired glucose tolerance.
by: Goldsworthy, M, et al.
Published: (2008)

International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.
by: Dos Santos, M, et al.
Published: (2017)

Prevalence of diabetes mellitus and impaired glucose tolerance in parents of women with gestational diabetes.
by: McLellan, J, et al.
Published: (1995)

Hyperglycaemic progression in subjects with impaired glucose tolerance: association with decline in beta cell function.
by: Cook, J, et al.
Published: (1993)

Prevalence and pathophysiology of impaired glucose tolerance in three different high-risk white groups.
by: Page, R, et al.
Published: (1993)

GLUCOSE-TOLERANCE AND BETA-CELL FUNCTION ASSESSED BY CONTINUOUS INFUSION OF GLUCOSE AND ORAL GLUCOSE-TOLERANCE TEST
by: Levy, J, et al.
Published: (1992)

Changes in forearm blood flow at elevated ambient temperature and their role in the apparent impairment of glucose tolerance.
by: Frayn, K, et al.
Published: (1989)

Diabetes and impaired glucose tolerance: a review of the epidemiological and trial evidence for their role in cardiovascular risk.
by: Bowman, L, et al.
Published: (2002)

Predicting risk for new-onset type 2 diabetes in Chinese people with coronary heart disease and impaired glucose tolerance
by: Xu, S, et al.
Published: (2019)

Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial
Published: (2008)

Frequency of abnormal glucose tolerance and the metabolic syndrome in people at increased cardiovascular disease risk screened for the NAVIGATOR trial
by: Holman, R, et al.
Published: (2003)

Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance
by: Xu, S, et al.
Published: (2021)

Histological features of symptomatic carotid plaques in patients with impaired glucose tolerance and diabetes (oxford plaque study).
by: Redgrave, J, et al.
Published: (2008)

Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease.
by: Farrer, M, et al.
Published: (1993)

Comparison of medical resources, costs, and health utilities among patients with CHD and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation Trial (ACE)
by: Mc Morrow, L, et al.
Published: (2018)

Evaluation of a self-administered oral glucose tolerance test
by: Bethel, M, et al.
Published: (2013)

Assessing the impact of blood sample type on the estimated prevalence of impaired glucose tolerance and diabetes mellitus in epidemiological surveys.
by: Farrer, M, et al.
Published: (1995)